Stay updated with breaking news from Year Safety. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Continuous Kesimpta® treatment maintained profound suppression of MRI lesion activity and resulted in an increase in the number of patients with relapsing forms of...
More than 80% of relapsing MS patients who took Kesimpta continuously for five years in a trial did not have any worsening of disability.
The ALITHIOS open-label extension study showed continuous treatment with Kesimpta® (ofatumumab) for up to five years in relapsing multiple sclerosis (RMS)...
05.12.2022 - SEATTLE, Dec. 05, 2022 (GLOBE NEWSWIRE) - Adaptive Biotechnologies Corporation (Nasdaq: ADPT), together with its collaborators, will present data from more than 30 abstracts showcasing the benefit of Adaptive’s next-generation sequencing ...
/PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE: SNN), the global medical technology company, today announces promising new data furthering a number of published...